RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00000171.xml
Dtsch Med Wochenschr 2011; 136(31/32): 1570-1573
DOI: 10.1055/s-0031-1281554
DOI: 10.1055/s-0031-1281554
Endokrinologie & Diabetologie | Commentary
Endokrinologie
© Georg Thieme Verlag KG Stuttgart · New York
Pharmakologische Konzepte zur Behandlung der Adipositas – ein therapeutischer Irrweg?
Pharmacological concepts for the treatment of obesity – a therapeutic meander?Weitere Informationen
Publikationsverlauf
Publikationsdatum:
01. August 2011 (online)
![](https://www.thieme-connect.de/media/dmw/20113132/lookinside/thumbnails/10.1055-s-0031-1281554-1.jpg)
Schlüsselwörter
Adipositas - Orlistat - Rimonabant
Keywords
obesity - orlistat - rimonabant
Literatur
- 1 Batterham R L, Cohen M A, Ellis S M. et al . Inhibition of food intake in obese subjects by peptide YY3 – 36. N Engl J Med. 2003; 349 941-948
- 2 Chaudhri O B, Wynne K, Bloom S R. Can gut hormones control appetite and prevent obesity?. Diabetes Care. 2008; 31 Suppl 2 S284-289
- 3 Day J W, Ottaway N, Patterson J T. et al . A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol. 2009; 5 749-757
- 4 Food and Drug Administration. FDA Issues Complete Response Letter for Lorcaserin New Drug Application 2010. http://invest.arenapharm.com/releasedetail.cfm?ReleaseID=521977 letzter Zugriff 4.7.2011
- 5 Field B C, Chaudhri O B, Bloom S R. Bowels control brain: gut hormones and obesity. Nat Rev Endocrinol. 2010; 6 444-453
- 6 Hauner H, Buchholz G, Hamann A. et al .Evidenzbasierte Leitlinie Therapie und Prävention der Adipositas. 2007. http://www.dge.de/pdf/ll/Adipositas-Leitlinie-2007.pdf letzter Zugriff 28.6.2010
- 7 Hollander P A, Elbein S C, Hirsch I B. et al . Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care. 1998; 21 1288-1294
- 8 Inui A, Asakawa A, Bowers C Y. et al . Ghrelin, appetite, and gastric motility: the emerging role of the stomach as an endocrine organ. Faseb J. 2004; 18 439-456
- 9 Li Z, Maglione M, Tu W. et al . Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med. 2005; 142 532-546
- 10 Roth J D, Roland B L, Cole R L. et al . Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies. Proc Natl Acad Sci U S A. 2008; 105 7257-7262
- 11 Rucker D, Padwal R, Li S K. et al . Long term pharmacotherapy for obesity and overweight: updated meta-analysis. Brit Med J. 2007; 335 1194-1199
- 12 Schindler C, Kirch W. Eine Lehrstunde zur Arzneimittelentwicklung am Beispiel Rimonabant?. Dtsch Med Wochenschr. 2010; 135 2064
- 13 Torp-Pedersen C, Caterson I, Coutinho W. et al . Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial. Eur Heart J. 2007; 28 2915-2923
- 14 World Health Organization .Obesity and overweight. WHO fact sheet N 311, March 2011.
- 15 Wright S M, Aronne L J. Obesity in 2010: the future of obesity medicine: where do we go from here?. Nat Rev Endocrinol. 2011; 7 69-70
Priv.-Doz. Dr. med. Christoph Schindler
Institut für Klinische Pharmakologie
Medizinische
Fakultät der TU Dresden
Fiedlerstr. 27
01307
Dresden
Telefon: 0351/458-2027
Fax: 0351/458-8918
eMail: christoph.schindler@tu-dresden.de